Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2024 | Link between hormone receptor status and outcomes in young patients with breast cancer

Lisa Carey • 31 May 2024
ASCO 2024
Breast Cancer

Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, discusses findings from a multicenter, retrospective study assessing the impact of hormone receptor status on clinical behavior and outcomes in patients with breast cancer under 40 years of age. Hormone receptor status did not seem to be a positive prognostic factor in patients with BRCA1/2 mutations. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Research Funding – AstraZeneca (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Lilly (Inst); NanoString Technologies (Inst); Novartis (Inst); Seagen (Inst); Veracyte (Inst)

More from Lisa Carey

EAZ171: taxane-induced peripheral neuropathy in Black women with breast cancer
2:25
EAZ171: taxane-induced peripheral neuropathy in Black women with breast cancer
Lisa Carey • 31 May 2024
Anti-Müllerian hormone as a predictor of chemotherapy response in HR+/HER2- breast cancer
1:33
Anti-Müllerian hormone as a predictor of chemotherapy response in HR+/HER2- breast cancer
Lisa Carey • 31 May 2024
Highlights from St. Gallen BCC 2023
0:57
Highlights from St. Gallen BCC 2023
Lisa Carey • 17 Mar 2023
Early breast cancer: do we need chemotherapy in low genomic/high clinical risk (ER+/HER2-)?
1:49
Early breast cancer: do we need chemotherapy in low genomic/high clinical risk (ER+/HER2-)?
Lisa Carey • 17 Mar 2023

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026
The content of VJOncology is intended for healthcare professionals